

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Campbell et al.

Title:

Acyl-Nucleotide Probes And

Methods Of Their Synthesis And

Use In Proteomic Analysis

Appl. No.:

10/817,454

Filing Date:

04/01/2004

Examiner:

Art Unit:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

DIFNE GAPCIA

(Printed Name)

(Signature)

7-14-04

(Date of Deposit)

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 CFR §1.56</u>

Mail Stop Amendment (IDS) Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without*

Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even

entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

FOLEY & LARDNER LLP Customer Number: 30542 Telephone: (858) 847-6714

Facsimile: (858) 792-6773

Wesley B. Ames

Attorney for Applicant Registration No. 40,893

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995 number.

duction Act of 1995 to persons are require

112011							
	Substitute f	or form 1449	B/PTO TRADEDAR	Complete if Known			
•	INFORMAT	ION DISCLO	DSURE	Application Number	10/817,454		
	STATEMEN	IT BY APPL	ICANT	Filing Date	04/01/2004		
				First Named Inventor	David Alan Campbell		
				Group Art Unit			
	(use as many	sheets as n	ecessary)	Examiner Name	·		
heet	1	of	4	Attorney Docket Number	063391-1802		

		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	A1	4,415,655		De Castro et al.	11-15-1983	
	A2	4,481,094		Fernandez de Castro et al.	11-06-1984	
	A3	4,865,707		Karger et al.	09-12-1989	
	A4	4,946,794		Berube	08-07-1990	
	A5	5,215,970		Datema et al.	06-01-1993	
	A6	6,008,373		Waggoner et al.	12-28-1999	
	A7	6,043,060		Imanishi	03-28-2000	
	A8	6,255,292		Liang	07-03-2001	
						·

				F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	Office	oreign Patent [³ Number ⁴	Document Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A9	WO	00/011208		University of Washington	03-02-2000		
	A10	WO	01/77668		The Scripps Research Institute	10-18-2001		
	A11	WO	01/77684		The Scripps Research Institute	10-18-2001		
	A12	WO	03/079014		Pharmacia Groningen BV	01-30-2003		
					•			

۸		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A13	Bergseid et al., Small molecule-based chemical affinity system for the purification of proteins. Biotechniques (2000) 29(5):1126-1133	
	A14	Bishop et al., Magic bullets for protein kinases. Trends Cell Biol (2001) 11(4):167-172	

Examiner Signature		¢	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B/	PTO	Complete if Known			
	INFORMATION D	ISCLO	SURE	Application Number	10/817,454		
	STATEMENT BY	APPLI	CANT	Filing Date	04/01/2004		
				First Named Inventor	David Alan Campbell		
				Group Art Unit			
	(use as many sheets	s as ne	cessary)	Examiner Name			
Sheet	2	of	4	Attorney Docket Number	063391-1802		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A15	Clauser, et al., Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc. Natl. Acad. Sci. USA (1995) 92:5072-76	
	A16	Daniel, SM et al., FastTag™ Nucleic Acid Labeling System: A Versatile Method for Incorporating Haptens, Fluorochromes and Affinity Ligands into DNA, RNA and Oligonucleotides. Biotechniques (1998) 24(3), 484-489	
	A17	De Leenheer, et al., Applications of isotope dilution-mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology. Mass Spectrom. Rev. (1992) 11:249-307	
	A18	Deutscher (ed.), Methods in Enzymology, (1990) vol. 182, pp. 147-238, chapter 12 by Cull and McHenry entitled "Preparation of extracts from Prokaryotes."	
	A19	Eisen et al., Cluster analysis and display of genome-wide expression patterns. <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95:14863-14868	
	A20	Eng. et al. An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database. J. Am. Soc. Mass Spectrom. (1994) 5:976-989	
	A21	Gibson et al., Nonpeptidic $\alpha_y \beta_3$ Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Agnew. Chem. Int. Ed. (2001) 40: 165-169.	
	A22	Gottschling et al., Cellular Solid-Phase Binding Assay and Mass Spectrometry for Screening of α4β7 Integrin Antagonists. Bioorg. And Medicinal Chem. Lett. (2001) 11: 2997	
2.	A23	Gygi et al., Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era. Mol. Cell. Biol. (1999) 19:1720-1730	
	A24	Gygi, et al., Correlation between Protein and mRNA Abundance in Yeast. Mol. And Cell. Biol. (1999) 20:310-319	

Examiner	,	Date	
Signature		Considered	ı
•			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	or form 1449B	/PTO	Complete if Known		
4	INFORMATI	ON DISCLO	SURE	Application Number	10/817,454	
	STATEMEN	T BY APPLI	CANT	Filing Date	04/01/2004	
				First Named Inventor	David Alan Campbell	
				Group Art Unit		
	(use as many s	sheets as ne	cessary)	Examiner Name		
Sheet	3	of	4	Attorney Docket Number	063391-1802	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	No.1 No.1 No.1 No.1 No.1 No.1 No.1 No.1					
	A25	Hanks and Hunter, "The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification." FASEB J. (1995) 9(8):576-596				
	A26	Kidd et al., Profiling Serine Hydrolast Activities in Complex Proteomes. Biochemistry (2001) 40: 4005-15				
	A27	Kolb et al., Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Agnew Chem. Int. Ed. Engl. (2001) 40: 2004-21				
,	A28	Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature (1970) 227:680-685				
	A29	Lemieux et al. A Fluorogenic Dye Activated by the Staudinger Ligation. J. Am. Chem. Soc. (2003) 125: 4708-4709				
	A30	Leon et al., Evaluation of Resins for On-Bead Screening: A Study of Papain and Chymotrypsin Specificity Using Pega-Bound Combinatorial Peptide Libraries. Bioorg. Med. Chem. Lett. (1998) 8: 2997				
	A31	Link, et al., Identifying the major proteome components of <i>Haemophilus influenzae</i> type-strain NCTC 8143. Electrophoresis (1997) 18:1314-34				
	A32	Mann and Wilm, Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags. Anal. Chem. (1994) 66:4390-99				

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute fo	or form 1449B	J/PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/817,454		
	STATEMEN	T BY APPL	ICANT ·	Filing Date	04/01/2004		
			-	First Named Inventor	David Alan Campbell		
				Group Art Unit		-	
	(use as many s	heets as ne	ecessary)	Examiner Name			
Sheet	4	of	4 .	Attorney Docket Number	063391-1802		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶		
	A33	Orain and Bradley, Solid phase synthesis of trypanothione reductase inhibitors-towards single bead screening. Tetrahedron Lett. (2001) 42: 515-518	,		
,	A34	Papanikos et al., a–Ketocarbonyl Peptides: A General Approach to Reactive Resin-Bound Intermediates in the Synthesis of Peptide Isosteres for Protease Inhibitor Screening on Solid Support. J. Am. Chem. Soc. (2001) 123: 2176 2181			
	A35	Porco, Organic Synthesis Using Chemical Tags: The "Third Leg" of Parallel Synthesis. JA Comb. Chem. High Throughput Screening (2000) 3(2) 93-102			
	A36	Ross et al., Systematic variation in gene expression patters in human cancer cell lines. <i>Nat. Genet.</i> (2000)24:227-235			
	A37	Seo et al., Click Chemistry to Construct Fluorescent Oligonucleotides for DNA Sequencing. J. Org. Chem. (2003) 68: 609-612			
	A38	Smith and Bradley, Comparison of Resin and Solution Screening of Methodologies in Combinatorial Chemistry and the Identification of a 100nM Inhibitor of Trypanothione Reductase. J. Comb. Med. (1999) 1: 326-332.			

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.